Navigation Links
Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
Date:5/23/2012

utics Market, The US Market, Annual Cost of Treatment ($), 2010-2018 65Table 41: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2004-2010 66Table 42: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2018 66Table 43: Arthritis Therapeutics Market, Top Five EU Countries, Revenue ($bn), 2004-2010 68Table 44: Arthritis Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2010-2018 68Table 45: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2004-2010 69Table 46: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2010-2018 69Table 47: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2004-2010 70Table 48: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2010-2018 71Table 49: Arthritis Therapeutics Market, Japan, Revenue ($bn), 2004-2010 72Table 50: Arthritis Therapeutics Market, Japan, Revenue Forecast ($bn), 2010-2018 72Table 51: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2010 73Table 52: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2018 73Table 53: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2004-2010 74Table 54: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2018 74Table 55: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 79Table 56: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 80Table 57: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Develoment Stage Molecules, 2011 80Table 58: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 81Table 59: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 201
'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
2. The Strong Womans Approach to Managing Rheumatoid Arthritis
3. Defect in A20 gene expression causes rheumatoid arthritis
4. Hospital for Special Surgery to Host International Arthritis Summit: Frontiers in Osteoarthritis Research, Prevention and Care
5. CrystalGenomics Initiates CG100649 Phase 2b Study in Patients with Osteoarthritis
6. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
7. TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee
8. Novel ACR Hybrid Score in Rheumatoid Arthritis Applied for the First Time to Data from the RAPID 1 Study with Cimzia® (certolizumab pegol)
9. Arthritis drug could help beat melanoma skin cancer
10. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
11. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... 1, 2015  Turing Pharmaceuticals AG announced that life ... , MD, MSc,  has joined the company as ... Salinas, who holds a medical degree as well ... of significant accomplishments in the pharmaceutical industry, and ... Salinas has played a leadership role in numerous ...
(Date:6/1/2015)... 1, 2015 GenomeDx Biosciences today ... platform, successfully classified various subtypes of bladder ... certain biomarkers, including one type associated with ... genomic signature has potential as a tool ... in patients with muscle-invasive bladder cancers (MIBC). ...
(Date:6/1/2015)... June 1, 2015 Research ... addition of the "Global PDT Machine Industry ...        (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... is a professional and in-depth study on the ... report provides a basic overview of the industry ...
(Date:6/1/2015)... , June 1, 2015  Fennec Pharmaceuticals, Inc. ... positive interim results from a poster presented today ... label randomised phase III trial of the efficacy ... patients receiving cisplatin (Cis) monotherapy for standard risk ... American Society of Clinical Oncology (ASCO) 2015 Annual ...
Breaking Biology Technology:Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Global PDT Machine Industry Report 2014 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4
... - Dr. Liew awarded Malaysia,s Darjah Yang Mulia ... - GeneNews Limited (TSX: GEN),a company focused on ... of diseases and personalized health management, today,announced that ... Liew,was awarded the Darjah Yang Mulia Pangkuan Negeri ...
... Imprint to Yield a Strong and ... Highly Specific Immune Response, ... ILNS) a biopharmaceutical company focused on,development of disease-modifying therapeutic agents ... announced today,that Dr. Rachel Eren, Vice President Research, will present ...
... Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT),announced that ... than,35% over the first quarter of 2007 exceeding $1,872,000 ... same period in the previous year. Revenues for ... only,$24,374 in the first half of 2006. These significant ...
Cached Biology Technology:GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia 2Intellect Neurosciences, Inc. to Present Data on Alzheimer's Vaccine at 13th International Congress of Immunology Conference 2Intellect Neurosciences, Inc. to Present Data on Alzheimer's Vaccine at 13th International Congress of Immunology Conference 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 4Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 5Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 6
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... for Secure and Resilient Maritime Commerce (CSR) at Stevens Institute ... Stevens was named by the US Department of Homeland Security ... and was selected to lead a national research effort to ... partner with the DHS and serve as an important team ...
... Ind. - One of the most common house ant species ... smallest spaces in a forest, but the ants have found ... Grzegorz Buczkowski, a Purdue University research assistant professor of ... more complex as they move from forest to city and ...
... their wide-view neurostimulator concept a bionic eye that ... technology. The prototype bionic eye, developed by ... and unveiled today at the BVA consortium,s official launch ... of life for patients suffering from degenerative vision loss ...
Cached Biology News:Common house ants form supercolonies, prosper in urban settings 2Bionic Vision Australia puts bionic eye in sight 2
... d1-174 GenBank Accession Number : NM_006225 ... tagged fusion protein corresponding to full length ... pH 7.4, 0.15M NaCl, 0.05% sodium azide ... Quality Assurance: routinely evaluated by immunoblot on ...
Request Info...
Request Info...
Mouse Galectin-1 Affinity Purified Polyclonal Ab...
Biology Products: